Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Healthtrust
Chubb
Mallinckrodt
Cipla
Queensland Health
Farmers Insurance
QuintilesIMS
Johnson and Johnson

Generated: April 23, 2018

DrugPatentWatch Database Preview

Mylan Institutional Company Profile

« Back to Dashboard

What is the competitive landscape for MYLAN INSTITUTIONAL, and when can generic versions of MYLAN INSTITUTIONAL drugs launch?

MYLAN INSTITUTIONAL has fifty-six approved drugs.

There is one US patent protecting MYLAN INSTITUTIONAL drugs.

Summary for Mylan Institutional
US Patents:1
Tradenames:49
Ingredients:47
NDAs:56

Drugs and US Patents for Mylan Institutional

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Institutional RIMSO-50 dimethyl sulfoxide SOLUTION;INTRAVESICAL 017788-001 Approved Prior to Jan 1, 1982 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Institutional MILRINONE LACTATE milrinone lactate INJECTABLE;INJECTION 076428-001 Jun 16, 2003 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Institutional IBUTILIDE FUMARATE ibutilide fumarate INJECTABLE;INJECTION 090643-001 Jan 11, 2010 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Institutional DIMETHYL SULFOXIDE dimethyl sulfoxide SOLUTION;INTRAVESICAL 076185-001 Nov 29, 2002 AT RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Mylan Institutional

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 5,866,591*PED ➤ Try a Free Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 5,019,583*PED ➤ Try a Free Trial
Mylan Institutional ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019678-001 Nov 6, 1991 4,952,586 ➤ Try a Free Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 5,019,583*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MYLAN INSTITUTIONAL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 100 mg/mL, 2.5 mL vials ➤ Subscribe 2007-09-24
➤ Subscribe for Injection 1 mg/vial, 2 mg/vial and 5 mg/vial ➤ Subscribe 2013-12-27
➤ Subscribe Injection 1 mg/mL, 50 mL vials ➤ Subscribe 2011-12-16
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Dow
Fish and Richardson
Mallinckrodt
Queensland Health
Johnson and Johnson
QuintilesIMS
Healthtrust
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.